Safinamide Mesylate CAS 202825-46-5

Product Description:

Product Name: Safinamide Mesylate CAS NO: 202825-46-5

Synonyms:

(S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propanamide;

(2S)-2-[[4-[(3-fluorophenyl)m-ethoxy]phenyl]methylamino]propanamide,methanesulfonic acid;

(S)-(+)-2-[[4-(3-Fluorobenzoxy)benzyl]amino]propanamide;

Chemical & Physical Properties:

Appearance: White solid

Assay :≥99.00%

Boiling Point: 476.7℃ at 760 mmHg

Flash Point: 242.1℃

Vapor Pressure: 2.98E-09mmHg at 25℃

Storage: -20℃ Freezer

Solubility: Acetic Acid (Sparingly), DMSO (Slightly), Methanol (Slightly)

Safety Information:

HS Code: 2924299090

Hazard Declaration: H301; H318; H400

Signal Word: Danger

Caution Statements: P273; P280; P301 + P310; P305 + P351 + P338

Symbols: GHS05, GHS06, GHS09

WGK Germany: 3

Safinamide (INN; brand name Xadago, former developmental code name EMD-1195686) is a drug indicated for the treatment of Parkinson's disease with multiple methods of action. In 2007, a Phase III clinical trial was started. It was scheduled to run until 2011. The compound was originally discovered at Farmitalia-Carlo Erba, first published in 1998 and developed by Newron Pharmaceuticals, which sold the rights to Merck-Serono in 2006. In October 2011 Merck-Serono announced that they would give all rights to develop the compound back to Newron.

Potential additional uses might be restless legs syndrome (RLS) and epilepsy. They were being tested in Phase II trials in 2008, but no results are available.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.